Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________

FORM 10-Q

____________

☑ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 000-23476

GROOVE BOTANICALS, INC.

(Exact Name of Small Business Issuer as specified in its charter)

Nevada		84-1168832
(State or other jurisdiction of incorporation or organization)		(I.R.S. employer identification no.)

310 Fourth Avenue South, Suite 7000

Minneapolis, MN 55415

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

(612) 315-5068

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☑	Smaller reporting company	☑
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

59,643,062 shares of our common stock were issued and outstanding as of February 13, 2024.

Table of Contents

		Page
PART I FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of December 31, 2023 (Unaudited) and March 31, 2023	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2022 and 2023 (Unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the Nine Months ended December 31, 2022 and 2023 (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operation	15
Item 3.	Qualitative and Quantitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

PART II OTHER INFORMATION
Item 1.	Legal Proceedings	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
Signatures		25

Groove Botanicals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


	(Unaudited)			(Audited)
	December 31,			March 31,
	2023			2023

ASSETS
Current Assets:
Cash and Cash Equivalents	$	2,150		$	4,566
Accounts Receivable		25			25
Prepaid Expenses		330			390
Total Current Assets		2,505			4,982

TOTAL ASSETS	$	2,505		$	4,982

LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts Payable and Accrued Liabilities	$	76,694		$	44,489
Interest Payable		—			14,678
Related Party Payable		411,442			301,100
Convertible Notes Payable		—			100,000
Dividends Payable - Related Party		163,853			—
Total Current Liabilities		651,989			460,267

Total Liabilities		651,989			460,267

Stockholders' Deficit
Preferred Stock, Series A, $0.10 par value, 100 shares authorized; 100 shares issued and outstanding as of December 31, 2023, and March 31, 2023		10			10
Preferred Stock, Series B, $0.10 par value, 2,000 shares authorized; 1,983 shares issued and outstanding as of December 31, 2023, and March 31, 2023		198			198
Common Stock, $0.001 par value, 200,000,000 shares authorized; 59,643,062 and 57,643,062 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively		59,643			57,643
Additional paid-in capital		33,951,511			33,903,511
Accumulated deficit		(34,660,846	)		(34,416,648	)

Total stockholder's deficit		(649,484	)		(455,285	)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT	$	2,505		$	4,982

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Groove Botanicals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)


	Three Months ended						Nine Months ended
	December 31,						December 31,
	2023			2022			2023			2022

Expenses:
Selling, General and Administrative Expenses	$	16,303		$	15,467		$	52,496		$	54,706
Rent		4,644			4,644			13,932			13,152
Legal and Professional Expenses		34,525			7,504			58,595			45,673
Consulting Expense		-			10,000			30,000			10,000
Total Operating Expenses		55,472			37,615			155,023			123,531

Operating Loss		(55,472	)		(37,615	)		(155,023	)		(123,531	)

Other Income (Expense)
Amortization of Debt Discount		—			(7,561	)		—			(69,451	)
Change in Derivative Liability		—			7,811			—			60,567
Gain on Settlement of Debt		82,178			—			82,178			25,000
Interest Expense		(2,500	)		(3,690	)		(7,500	)		(11,496	)
Total Other Income (Expense)		79,678			(3,440	)		74,678			4,620

Net income (loss)	$	24,206		$	(41,055	)	$	(80,345	)		(118,911	)

Dividend on Preferred Stock		54,618			-			163,853			-
Loss attributed to common stockholders	$	(30,412)		$	(41,055	)	$	(244,198)		$	(118,911	)

Basic and Diluted Earnings (Loss) per Common Share	$	0.00		$	(0.00	)		(0.00	)	$	(0.00	)

Weighted Average Common Shares Outstanding – Basic and diluted		58,762,627			53,309,366			60,974,239			52,479,244

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Groove Botanicals, Inc.

Condensed Consolidated Statements of Stockholders' Equity

For the Nine Months Ended December 31, 2022


	Series A Preferred Stock			Series B Preferred Stock			Common Stock			Common Stock to be Issued					Additional Paid In Capital		Accumulated Deficit			Total
	Shares	Amount		Shares	Amount		Shares	Amount		Shares		Amount			Amount		Amount			Amount

Balance, March 31, 2022 (Audited)	100	$	10	1,983	$	198	49,193,062	$	49,193	3,000,000		$	3,000		$	33,798,656	$	(34,305,992	)	$	(454,935	)
Issuance of Stock for Cash Received in Prior Period	—		—	—		—	3,000,000		3,000	(3,000,000	)		(3,000	)		—		—			—
Net Income	—		—	—		—	—		—	—			—			—		23,745			23,745
Balance, June 30, 2022 (Unaudited)	100	$	10	1,983	$	198	52,193,062	$	52,193	—		$	—		$	33,798,656	$	(34,282,247	)	$	(431,190	)

Net Loss	—		—	—		—	—		—	—			—			—		(101,601	)		(101,601	)
Balance, September 30, 2022 (Unaudited)	100	$	10	1,983	$	198	52,193,062	$	52,193	—		$	—		$	33,798,656	$	(34,383,848	)	$	(532,791	)

Issuance of Stock for Cash	—		—	—		—	2,150,000		2,150	-			-			40,813		—			42,963
Issuance of Stock for Consulting	—		—	—		—	500,000		500	-			-			9,500		—			42,963
Net Loss	—		—	—		—	—		—	—			—			—		(41,055	)		(41,055	)
Balance, December 31, 2022 (Unaudited)	100	$	10	1,983	$	198	54,843,062	$	54,843	—		$	—		$	33,848,969	$	(34,424,903	)	$	(520,883	)

Groove Botanicals, Inc.

Consolidated Statements of Stockholders' Equity

For the Nine Months Ended December 31, 2023

	Series A Preferred Stock			Series B Preferred Stock			Common Stock			Common Stock to be Issued			Additional Paid In Capital		Accumulated Deficit			Total
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Amount		Amount			Amount

Balance, March 31, 2023 (Audited)	100	$	10	1,983	$	198	57,643,062	$	57,643	—	$	—	$	33,903,511	$	(34,416,648	)	$	(455,285	)
Issuance of Stock for Consulting	—		—	—		—	1,000,000		1,000	—		—		29,000		—			30,000
Accrual of Preferred Dividends to Related Party	—		—	—		—	—		—	—		—		—		(54,618	)		(54,618	)
Net Loss	—		—	—		—	—		—	—		—		—		(77,144	)		(77,144	)
Balance, June 30, 2023 (Unaudited)	100	$	10	1,983	$	198	58,643,062	$	58,643	—	$	—	$	33,932,511	$	(34,548,410	)	$	(557,048	)

Accrual of Preferred Dividends to Related Party	—		—	—		—	—		—	—		—		—		(54,618	)		(54,618	)
Net Loss	—		—	—		—	—		—	—		—		—		(27,406	)		(27,406	)
Balance, September 30, 2023 (Unaudited)	100	$	10	1,983	$	198	58,643,062	$	58,643	—	$	—	$	33,932,511	$	(34,630,434	)	$	(639,072	)

Issuance of Stock for Cash							1,000,000		1,000					19,000					20,000
Accrual of Preferred Dividends to Related Party	—		—	—		—	—		—	—		—		—		(54,618	)		(54,618	)
Net Income	—		—	—		—	—		—	—		—		—		24,206			24,206
Balance, December 31, 2023 (Unaudited)	100	$	10	1,983	$	198	59,643,062	$	59,643	—	$	—	$	33,951,511	$	(34,660,846	)	$	(649,484	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Groove Botanicals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	For the Nine Months Ended
	December 31,
	2023			2022

Cash Flow From Operating Activities
Net (Loss)	$	(80,345	)	$	(118,911	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of Debt Discount		—			69,451
Change in Derivative Liability		—			(60,567	)
Gain on Settlement of Debt		(82,178	)		(25,000	)
Stock-Based Compensation for Consulting		30,000			10,000
Accrued Interest		7,500			11,496
Accrued Payroll		36,000			36,000
Accounts Payable and Accrued Liabilities - Related Party		—			3,044
Changes in working capital
Decrease in Accounts Receivable		—			226
Decrease in Prepaid Expenses		60			—
Increase (Decrease) in Accounts Payable and Accrued Liabilities		32,205			(1,019	)
Net Cash Used in Operating Activities		(56,758	)		(75,280	)

Cash Flow From Investing Activities
Net Cash Provided by (Used in) Investing Activities		—			—

Cash Flow From Financing Activities
Funds Received from Related Party		76,393			158,000
Funds Distributed to Related Party		(2,051	)		(11,236	)
Funds received from issuance of common stock		20,000			42,963
Repayment of Outstanding Convertible Debt		(40,000	)		(64,650	)
Repayment of Outstanding Contingent Liability		—			(70,350	)
Net Cash Provided by (Used in) Financing Activities		54,342			54,727

Net Change in Cash		(2,416	)		(20,553	)

Cash at Beginning of Period		4,566			48,534

Cash at End of Period	$	2,150		$	27,980

Net cash paid for:
Interest	$	—		$	—
Income Taxes	$	—		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

GROOVE BOTANICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022

(UNAUDITED)

NOTE 1 - ORGANIZATION AND OPERATIONS

Current Operations

Groove Botanicals (“GRVE” or the “Company” or the “Corporation”), a Nevada corporation, is a publicly quoted independent oil and gas producer.

Corporate History

In May 1999, we changed our state of domicile to Nevada and our name to XDOGS.COM, Inc.

On July 31, 1998, the Corporation split their shares One (1) for Fifty-Four (54).

On August 24, 2000, the Corporation split their shares One (1) for Five (5) and changed our name from XDOGS.COM to XDOGS, Inc. We changed our symbol from XDGS to XDGI.

On June 22, 2005, the Corporation changed our name from XDOGS, Inc. to Avalon Oil and Gas, Inc. We changed our symbol from XDGI to AOGS.

On July 22, 2005, the Board of Directors and a majority of the Company's shareholders approved an amendment to our Articles of Incorporation to change the Company's name to Avalon Oil & Gas, Inc., and to increase the authorized number of shares of our common stock from 200,000,000 shares to 1,000,000,000 shares par value of $0.001.

On May 15, 2007, the Corporation split their shares One (1) for Twenty (20). We changed our symbol from AOGS to AOGN.

On June 4, 2012, the Board of Directors approved an amendment to our Articles of Incorporation to a reverse split of the issued and outstanding shares of Common Stock of the Corporation (“Shares”) such that each holder of Shares as of the record date of June 4, 2012, shall receive one (1) post-split Share on the effective date of June 4, 2012 for each three hundred (300) Shares owned. The reverse split was effective on July 23, 2012.

On September 28, 2012, we held a special meeting of Avalon’s shareholders and approved an amendment to the Company’s Articles of Incorporation such that the Company would be authorized to issue up to 200,000,000 shares of common stock. We filed an amendment with the Nevada Secretary of State on April 10, 2013, to increase our authorized shares to 200,000,000.

On July 23, 2012, the Corporation split their shares One (1) for Three Hundred (300).

On May 14, 2018, the Corporation changed our name from Avalon Oil and Gas, Inc., to Groove Botanicals, Inc. We changed our symbol from AOGN to GRVE. On September 14, 2023, we filed a Form 10 with the Securities and Exchange Commission which will become effective on November 13, 2023.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) for unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited consolidated financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. The audited consolidated balance sheet as of March 31, 2023, was derived from the Company’s audited consolidated financial statements at that date.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.

Financial Instruments

Pursuant to ASC Topic 820, Fair Value Measurements, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share gives the effect to all dilutive potential common shares outstanding during the period, including stock options, warrants and convertible instruments. Diluted net loss per share excludes all potentially issuable shares if their effect is anti-dilutive. Under the provisions of ASC 260, “Earnings per Share,” basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The Company has excluded some instruments from its dilutive shares calculations due to the instruments being anti-dilutive. These instruments previously referenced are convertible preferred shares, specifically Series A preferred shares which can be converted into common shares which after their conversion, would be equal to 51% of the issued and outstanding common stock following the moment of conversion. Furthermore, on January 12, 2018, our Board of Directors agreed that the Designation of the Series A Convertible Preferred Stock be amended by changing the ratio for conversion, in Article IV, subparagraph (a), from 0.4% to 0.51% so that upon conversion the number of shares of common stock to be exchanged shall equal 51% of then issued and outstanding common stock.

Recently Adopted Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

On December 18, 2019, the FASB issued ASU 2019-12 which modifies ASC 740 to simplify the accounting for income taxes. The ASU’s amendments are based on changes that were suggested by stakeholders as part of the FASB’s simplification initiative (i.e., the Board’s effort to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users).

ASC 740-10-25, “Accounting for Uncertainty in Income Taxes”, is intended to clarify the accounting for uncertainty in income taxes recognized in a company’s financial statements and prescribes the recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740-10-25 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

Under ASC 740-10-25, evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step it to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met.

Beneficial Conversion Feature

The Company measures its convertible debt using a nondetachable conversion feature known as a beneficial conversion feature, or BCF. A convertible instrument contains a BCF when the conversion price is less than the fair value of the shares into which the instrument is convertible at the commitment date. From time to time, the Company may issue convertible notes that may contain a beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Debt Issuance Cost

Debt issuance costs incurred in connection with the issuance of debt are capitalized and amortized to interest expense over the term of the debt using the effective interest method. The unamortized amount is presented as a reduction of debt on the balance sheet.

In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20 that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. Two methods of transition were permitted upon adoption: full retrospective and modified retrospective. The Company has yet to adopt ASC 2020-06, and expects to adopt this policy on January 1, 2024. The accounting impact will be a reclassification from Additional Paid-In Capital to Retained Earnings.

NOTE 3 - GOING CONCERN

The accompanying condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $80,345 and $118,911 for the nine months ended December 31, 2023, and December 31, 2022, respectively. The Company's accumulated deficit was $34,660,846 and $34,416,648 as of December 31, 2023, and March 31, 2023, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing. Our auditors express substantial doubt about our ability to continue as a going concern.

NOTE 4 – CASH

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2023, the Company’s cash consisted of non-restricted cash.

NOTE 5 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company's financial instruments are cash, accounts receivable, accounts payable, notes payable, notes receivable and their carrying amounts are approximate their fair values based on their short-term nature. The recorded values of notes payable and notes receivable approximate their fair values, as interest approximates market rates. Furthermore, the Company had derivative liabilities in its prior fiscal year, which it considered to be a level 3 liability. For more information on the valuation method used for determining the value of the derivative liability, see Note 11.

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (“GAAP”) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3		Pricing inputs that are generally observable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. A slight change in unobservable inputs such as volatility can significantly have a significant impact on the fair value measurement of the derivatives liabilities.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments.

NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

The Company had accounts payable and accrued liabilities of $49,694 and $44,489 outstanding as of December 31, 2023, and March 31, 2023, respectively. These amounts consist of billings to the Company from its various service providers.

NOTE 7 – RELATED PARTY TRANSACTIONS

The Company had a related party payables of $411,442 and $301,100 outstanding as of December 31, 2023, and March 31, 2023, respectively. These amounts consist of funds contributed by the management for the purpose of providing financing during periods of low or negative cashflow in order to cover essential costs of continuing operations, as well as funds payable to management as compensation. On an annual basis the company accrues $48,000 of wages payable, $4,000 monthly, to its CEO Kent Rodriguez. On April 1, 2020, the Company entered into an employment agreement with its CEO which designates monthly payments due to CEO Kent Rodriguez in the amount of $4,000 each month. This agreement shall continue for four years until March 31, 2024. These payables accrue no interest and have no maturity date.

On June 3, 2022, the Company received a loan from a related party in the amount of $125,000. These funds were wired to the Company to help it reach settlement of the debts described in the following paragraph.

During the nine months ended December 31, 2023, the Company received accumulated advances for operational shortfalls of $76,393 from a related party.

NOTE 8 – CONVERTIBLE NOTES PAYABLE

(a)

The convertible notes payable consisted of a $230,000 Convertible Promissory Note issued on January 30, 2018, to a third party in exchange for cash. Beginning on the issuance date of the Note, the outstanding principal balance of this note accrued annual interest at 10%. The note had a maturity date of January 30, 2019. The note was booked with a debt discount of the full principal balance of $230,000, plus an excess amount booked to interest in the amount of $27,957, as of March 31, 2019. As of March 31, 2021, this entire debt discount had been amortized. Additionally, the note had a variable conversion price per share of a 40% discount to the lowest trading price of the previous five trading days prior to the conversion date. Subsequently there was a settlement agreement on June 3, 2021, in which the Company recognized an outstanding convertible debt and related contingent liability pertaining to an outstanding settlement in the amounts of approximately $54,650 and $95,350, respectively. This recognition came as part of a settlement agreement reached on June 3, 2021, in which the prior $230,000 convertible note, as well as approximately $72,458 of related interest was settled into a new convertible debt of $54,650, a contingent liability of $95,350, and two cash payments of $50,000 each to the note holder, which were made on July 20, 2020, and March 10, 2021. This transaction resulted in a gain on debt extinguishment of approximately $52,000. The convertible debt portion had no interest accrual and had a variable conversion price per share of a 60% discount to the average of the previous five-day trading closing bid price. There was also an amendment of the settlement agreement on June 3, 2022, the Company satisfied one of its outstanding convertible debts and related contingent liability in the amounts of approximately $55,000 and $95,000, respectively, via a settlement payment of $125,000, this resulted in a gain on the settlement of debt in the amount of $25,000. Both debts arose on June 3, 2021, when a previous $230,000 convertible note, as well as approximately $72,000 of related interest was then restructured via a settlement agreement into a new convertible debt, related contingent liability, and two corresponding cash payments of $50,000 each. As of March 31, 2023, the debt has been completely paid off and no longer exists.

(b)

The convertible notes payable also consists of a $40,000 Convertible Promissory Note issued on March 5, 2021, by management to a third party in exchange for professional services. Beginning on the issuance date of this note, the outstanding principal balance of this note shall bear annual interest at 10%, with interest commencing on the sixth month anniversary of the Issuance Date. The note has a maturity date of June 30, 2022. Additionally, the note has a fixed conversion feature of $0.02 per share, and therefore the Convertible Note is measured at the net of Debt Discount, calculated based off its Beneficial Conversion Features. The note was booked with a debt discount of the full principal balance of $40,000. As of December 31, 2022, this entire debt discount has been amortized, with $37,151 and $2,849 being amortized during the years ended March 31, 2022, and March 31, 2021, respectively. Therefore, as of both December 31, 2022, and March 31, 2021, no corresponding debt discount remained. The balance of the Convertible Promissory Note due to the Holder remained at Forty Thousand Dollars ($40,000) as of December 31, 2022. On January 23, 2023, the Company and the convertible note holder mutually agreed to settle this outstanding convertible note as well as a second note detailed below in item 8(e) in the principal amount of $60,000 and all interest accrued through settlement date for one cash payment of $40,000. In December 2023 the Company paid cash in the amount of $40,000 pursuant to this settlement agreement and the Company recorded a gain on debt settlement of $82,178 including interest forgiven of $22,178. As of December 31, 2023 and March 31, 2023, the balance of the convertible note was $0 and $40,000, respectively.

(c)

On July 23, 2021, the Company issued a convertible promissory note in the amount of $45,000, with an annual interest rate of 8% and a variable conversion price per share of a 40% discount to the average of the previous three-day trading closing bid price, in exchange for professional and legal services to be rendered. The convertible amount is accounted for based off the outstanding principal and related interest pertaining to the portion of the convertible debt instrument being converted, multiplied by the previously specified conversion rate. Also, as part of this agreement, common stock was granted equal to 14.9% of the outstanding common shares at the time of issuance, and the stock was transferred in three equal parts to affiliates holding the note; this transaction is detailed in the next paragraph. The note has a maturity date of March 31, 2023. The Company has made a total repayment of 20,000 on this debt as of December 31, 2022. The note had a balance of $25,000 and 35,000 as of December 31, 2022, and March 31, 2022, respectively. On March 28, 2023, the Company and the convertible promissory note holder mutually agreed to settle the outstanding convertible note issued on March 23, 2021, in the original amount of $45,000, with a remaining balance of $30,000 and all accrued interest for $5,000. The $5,000 was wired on March 29, 2023. As of March 31, 2023, the debt has been completely paid off and no longer exists.

(d)

On October 1, 2021, the Company issued a convertible promissory note in the amount of $50,000, with an annual interest rate of 5% and a fixed conversion price of $0.02 per share, in exchange for $50,000 received. The note was booked with a debt discount of the full principal balance of $50,000. As of December 31, 2022, the full $50,000 of the debt discount has been amortized. This note had a maturity date of September 30, 2022. Per a board resolution dated February 21, 2023, and corresponding notice of conversion dated February 22, 2023, all debt (principal and interest) related to this convertible note was converted to 2,750,000 shares of common stock, with the conversion effective as of January 31, 2023. These shares were issued to Mill End Capital, Ltd., per correspondence the CEO Kent Rodriguez sent to the Company’s Transfer Agent dated March 1, 2023. As of March 31, 2023, the debt has been completely satisfied and no longer exists.

(e)

On March 7, 2022, the Company issued a convertible promissory note in the amount of $60,000, with a maturity date of March 7, 2023, an annual interest rate of 10% and a fixed conversion price of $0.02 per share, in exchange for consulting services. The convertible amount is accounted for based off the outstanding principal and related interest pertaining to the portion of the convertible debt instrument being converted, multiplied by the previously specified conversion rate. On January 23, 2023, the Company and the convertible note holder mutually agreed to settle this outstanding convertible note as well as a second note detailed above in item 8(b) in the principal amount of $40,000 and all interest accrued through settlement date for one cash payment of $40,000. In December 2023 the Company paid cash in the amount of $40,000 pursuant to this settlement agreement and the Company recorded a gain on debt settlement of $82,178 including interest forgiven of $22,178. As of December 31, 2023 and March 31, 2023, the balance of the convertible note was $0 and $60,000, respectively.

The Company had convertible notes payable of $0 and $100,000 outstanding as of December 31, 2023, and March 31, 2023.

Schedule of convertible note payable
	December 31, 2023		March 31, 2023
Beginning Balance	$	100,000	$	164,774
Repayments in cash		(40,000)		(139,650	)
Extinguishment under settlement agreement		(60,000)		(139,650	)
Amortization of discounts		—		74,876
Convertible notes payable, net (Ending Balance)	$	—	$	100,000

Below is the summary of the principal balance and debt discounts as of December 31, 2023:


Convertible Promissory Note Holder	Start Date	End Date	Initial Note Principal Balance	Debt Discounts as of Issuance	Amortization	Debt Discounts as of December 31, 2023 and March 31, 2023
Robert Hymers III	3/5/2021	6/30/2022	$40,000	$40,000	($40,000)		—
Robert Hymers III	3/7/2022	3/7/2023	$60,000	$30,000	($30,000)		—
Total							—
Remaining note principal balance						$	—
Total convertible promissory notes, net						$	—

NOTE 9 – PREFERRED STOCK

The Company is authorized to issue 1,000,000 shares of Preferred Stock. We have authorized 100 shares of Series A Preferred Stock and 2,000 shares of Series B Preferred Stock, respectively, both with a par value of $0.10. As of December 31, 2023 and March 31, 2023, there were 100 and 1,983 shares issued and outstanding for Series A Preferred Stock and Series B Preferred Stock, respectively.

Series A Preferred Stock holds designations of cash dividends at the rate of 8% of the amount per share of Series A Preferred Stock per annum in the form of “Preferred Dividends”, voting rights on an as-converted to Common Stock basis, liquidation preferences, and conversion rights in which each share of Series A Preferred Stock shall, upon conversion, represent 0.51% of the then “Fully-Diluted Shares Outstanding” of the Company. On January 12, 2018, our Board of Directors agreed to amend Designation of the Series A Convertible Preferred Stock be amended by changing the ratio for conversion, in Article IV, subparagraph (a), from 0.4% to 0.51% so that upon conversion the number of shares of common stock to be exchanged shall equal 51% of then issued and outstanding common stock. In addition, on January 12, 2018, the Company and the Series A Holder agreed to forgive all accrued interest to date on the Series A, and to pause any accruals until April 1, 2023. The Series A Convertible Preferred Stock carries liquidating preference, over all other classes of stock, equal to the amount paid for the stock plus any unpaid dividends. Currently the value of the liquidation preference is $500,000, the amount of debt that the related party converted into the preferred stock. If this Preferred Stock were to be redeemed by the holder, it would result in an aggregate of the $500,000 liquidation preference, on a per share basis, this would equal $5,000 per share. The Company and Series A Preferred Holder agreed to forgive all accrued interest and arrearages in preferred share dividends of Series A Preferred Stock through March 31, 2023. Dividends began to accrue on the Series A Preferred Stock as of April 1, 2023. During the three and nine months ended December 31, 2023, the holder of the Series A preferred shares accrued $10,000 and $30,000 in preferred dividends from the Series A preferred shares.

Series B Preferred Stock holds designations of being ranked junior to the Series A Preferred Stock, cash dividends at the rate of 9% of the amount per share of Series B Preferred Stock per annum in the form of “Preferred Dividends”, a dividend received deduction for federal income tax purposes, liquidation preferences ranked junior to the Series A Preferred Stock, redemption of the Series B Preferred Stock by the Company at 105% of the Stated Value, plus accrued and unpaid Dividends, if prior to the two year anniversary of the Issuance Date, or at 100% of the State Value, plus accrued and unpaid Dividends, if on or after the two year anniversary of the Issuance Date, no voting rights, and right to notice of certain corporate action. All accrued dividends on the Series B has been settled through March 31, 2023, and none currently remains outstanding. Dividends began to accrue on the Series B Preferred Stock as of April 1, 2023. During the three and nine months ended December 31, 2023, the holder of the Series B preferred shares accrued $44,617 and $133,853, in preferred dividends from the Series B preferred shares.

NOTE 10 – COMMON STOCK

The Company is authorized to issue 200,000,000 shares of Common Stock, with a par value of $0.001.

On April 8, 2022, the Company issued 500,000 shares of common stock, 250,000 each to two separate parties, of which it had previously committed in exchange for $10,000 it had received, $5,000 from each party, received on March 22, 2022.

On April 8, 2022, the Company issued 2,500,000 shares of common stock, of which it had previously committed in exchange for $40,000 it had received on March 23, 2022.

On April 15, 2023, the Company issued 1,000,000 shares of common stock in exchange for consulting services. These shares were valued at $0.03 per shares per their corresponding consulting agreement.

On December 20, 2023, the Company issued 1,000,000 shares of common stock in exchange for $20,000 in cash proceeds.

The Company had 59,643,062 and 57,643,062 shares of common stock issued and outstanding as of December 31, 2023, and March 31, 2023, respectively.

NOTE 11 – DERIVATIVE FINANCIAL INSTRUMENTS

Our Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. The fair value of derivative instruments is recorded and shown separately under liabilities. Changes in the fair value of derivatives liability are recorded in the consolidated statement of operations under other (income) expense. For stock-based derivative financial instruments, the Company uses Black-Scholes Option Pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of December 31, 2023, and March 31, 2023, the Company had no outstanding derivative liabilities.

NOTE 12: COMMITMENTS AND CONTINGENCIES

As of December 31, 2023, the Company has a month-to-month verbal lease agreement with the landlord, in which the Company is obligated to pay $1,200 on a monthly basis.

In the normal course of business, we are subject to potential claims and disputes related to our business, including disputes with third parties over financing arrangements, as well as over service agreements with contractors. Some of these matters may be covered by our insurance and risk management programs or may result in claims or adjustments with our carriers. Management does not believe that the outcome of any of the legal proceedings to which the Company is a party will have a material adverse effect on its financial position or results of operations.

On January 30, 2018, the Company issued a $230,000 Convertible Promissory Note to a third party in exchange for cash. Subsequently there was a settlement agreement on June 3, 2021, in which the Company recognized an outstanding convertible debt and related contingent liability pertaining to an outstanding settlement in the amount of $54,650 and $95,350, respectively. This recognition came as part of a settlement agreement reached on June 3, 2021, in which the prior $230,000 convertible note, as well as approximately $72,458 of related interest was settled into a new convertible debt of $54,650, a contingent liability of $95,350, and two cash payments of $50,000 each to the note holder, which were made on July 20, 2020, and March 10, 2021. This transaction resulted in a gain on debt extinguishment of approximately $52,000. The convertible debt portion has no interest accrual and has a variable conversion price per share of a 60% discount to the average of the previous five-day trading closing bid price. On June 3, 2022, the Company received a loan from a related party in the amount of $125,000. There funds were wired to the Company to help it reach settlement of the debts described earlier within this paragraph.

On June 3, 2022, the Company satisfied the convertible debt and related contingent liability mentioned in the preceding paragraph in the amounts of $54,650 and $95,350, respectively, via a settlement payment of $125,000, this resulted in a gain on the settlement of debt in the amount of $25,000.

NOTE 13 – SUBSEQUENT EVENTS

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing apart from the following:

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled “Risk Factors” in our Form 10 as filed with the Securities and Exchange Commission (the “SEC”) on April 18, 2023 and our Form 10-K/A as filed on November 6, 2023, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.

The management’s discussion and analysis of our financial condition and results of operations are based upon our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements for the three and nine months ended December 31, 2023, and the notes thereto appearing elsewhere in this Report and the Company’s audited financial statements for the fiscal year ended March 31, 2023 included in our Form 10 as filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2023.

General Overview

Groove Botanicals, Inc. (the "Company"), (formerly known as Avalon Oil & Gas, Inc.), was originally incorporated in Colorado in April 1991 under the name Snow Runner (USA), Inc. The Company was the general partner of Snow Runner (USA) Ltd.; a Colorado limited partnership to sell proprietary snow skates under the name "Sled Dogs" which was dissolved in August 1992. In late 1993, the Company relocated its operations to Minnesota and in January 1994 changed our name to Snow Runner, Inc. In November 1994 we changed our name to the Sled Dogs Company. On July 31, 1998, the Corporation split their shares One (1) for Fifty-Four (54). In May 1999, we changed our state of domicile to Nevada and our name to XDOGS.COM, Inc. On August 24, 2000, the Corporation split their shares One (1) for Five (5) and changed our name from XDOGS.COM to XDOGS, Inc. We changed our symbol from XDGS to XDGI. On June 22, 2005, the Corporation changed our name from XDOGS, Inc. to Avalon Oil and Gas, Inc. We changed our symbol from XDGI to AOGS. On July 22, 2005, the Board of Directors and a majority of the Company's shareholders approved an amendment to our Articles of Incorporation to change the Company's name to Avalon Oil & Gas, Inc., and to increase the authorized number of shares of our common stock from 200,000,000 shares to 1,000,000,000 shares par value of $0.001. On May 15, 2007, the Corporation split their shares One (1) for Twenty (20). We changed our symbol from AOGS to AOGN. On June 4, 2012, the Board of Directors approved an amendment to our Articles of Incorporation to a reverse split of the issued and outstanding shares of Common Stock of the Corporation (“Shares”) such that each holder of Shares as of the record date of June 4, 2012 shall receive one (1) post-split Share on the effective date of June 4, 2012 for each three hundred (300) Shares owned. The reverse split was effective on July 23, 2012. On September 28, 2012, we held a special meeting of Avalon’s shareholders and approved an amendment to the Company’s Articles of Incorporation such that the Company would be authorized to issue up to 200,000,000 shares of common stock. We filed an amendment with the Nevada Secretary of State on April 10, 2013, to increase our authorized shares to 200,000,000. On July 23, 2012, the Corporation split their shares One (1) for Three Hundred (300). On May 14, 2018, the Corporation changed our name from Avalon Oil and Gas, Inc., to Groove Botanicals, Inc. We changed our symbol from AOGN to GRVE. On August 2, 2021, we filed a Form 15-12B to suspend our duty to file reports under sections 13 and 15(d) of the securities exchange act of 1934. We filed a Form 10 Registration Statement, as amended, on September 14, 2023 which became effective on November 13, 2023.

Present Operations

We plan to assemble a portfolio of early-stage EV Battery Technologies developed from Universities in Norway, Sweden and Finland, and seek grants from the State of Minnesota Department of Economic Development to find and identify corporate partners to commercialize these technologies and ultimately produce revenues for the Company. The Company does not currently own any patents or technologies related to the EV battery industry, and the process to acquire patents and technologies can be costly, and as such, the Company is not guaranteed to acquire any such patents.

As the Company continues its business development and asset acquisitions, the Company anticipates our capital needs to be between $500,000 and $5,000,000 (varying based on growth strategies).

Employees

We have one full time employee, our President, Kent Rodriguez and a part time administrative assistant. The Board retains consultants and advisors on as needed basis. They are compensated with cash and also with the issuance of the Company’s common stock.

Facilities

Our corporate office is located at 310 Fourth Avenue South, Suite 7000, Minneapolis, Minnesota 55415. This office space is leased from an unaffiliated third party on a month-to-month lease, for a monthly rental of $1,200.

Results of Operations

Overview

RESULTS OF OPERATIONS AND PLAN OF OPERATION

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and notes related thereto. The discussion of results, causes and trends should not be construed to infer conclusions that such results, causes or trends necessarily will continue in the future.

For the three months ended December 31, 2023 and 2022

Revenue

During the three months ended December 31, 2023 and 2022 the Company did not report any revenue from operations.

Operating Expenses

	Three Months ended
	December 31,
	2023		2022

Expenses:
Selling, General and Administrative Expenses	$	16,303	$	15,467
Rent		4,644		4,644
Legal and Professional Expenses		34,525		7,504
Consulting Expense		—		10,000
Total Operating Expenses	$	55,472	$	37,615

During the three months ended December 31, 2023 and 2022 the Company incurred operating expenses of $55,472 and $37,615 respectively. Selling, general and administrative expenses for the three months ended December 31, 2023 were $16,303 an increase of $836, compared to selling, general and administrative expenses of $15,467 during the three months ended December 31, 2022. Selling, general and administrative expenses for the three months ended December 31, 2023, consisted primarily of payroll and related costs of $12,000, and other selling, general, and administrative expenses of $4,303. Selling, general and administrative expenses for the three months ended December 31, 2022 consisted primarily of payroll and related costs of $12,000 and administrative expenses of $3,467. The slight increase was primarily due to an increase in other general, and administrative expenses in the three months ended December 31, 2023 including Edgar filing fees and other reporting costs, when compared with the three months ended December 31, 2022. Legal fees and professional fees were substantially increased from $7,504 in the three months ended December 31, 2022 to $34,525 in the three months ended December 31, 2023 predominantly as a result of fees associated with review engagements performed by our independent registered accounting firm with respect to our quarterly reporting requirements. Rent expense over the comparative three months were consistent at $4,644 and $4,644, respectively for the three months ended December 31, 2023 and 2022. There were no consulting expenses in the three months ended December 31, 2023 as compared to $10,000 in consulting fees in the prior comparative three month period ended December 31, 2022.

Other Income/(Expense)

During the three months ended December 31, 2023 the Company recorded other income of $79,678 as compared to other expense of $3,440 in the three months ended December 31, 2022.

Amortization of Debt Discount

Amortization of debt discounts for the comparative three-month periods ended December 31, 2023, and 2022 totaled $0 and $7,561, respectively. The Company fully amortized remaining debt discounts during the fiscal year ended March 31, 2023.

Gain on Settlement of Debt

Gain on settlement of debt for the comparative three-month periods ended December 31, 2023 and 2022 were $82,178 and $0, respectively, as the Company fulfilled the terms of a prior negotiated debt settlement agreement in the current three month period and retired $100,000 in convertible debt with a cash payment of $40,000, and wrote off previously accrued interest of $22,178.

Change in Derivative Liability

The Company recorded a gain of $7,811 with respect to the change in derivative liabilities for the three months ended December 31, 2022, with no comparative results in the three months ended December 31, 2023.

Interest Expense

Interest expense for the comparative three months ended December 31, 2023 and 2022 totaled $2,500 and $3,690, respectively. The decrease to interest expense was directly related to a reduction to the principal balances of certain convertible debt period over period.

Net Loss

For the reasons stated above, we reported net income of $24,206 for the three months ended December 31, 2023 compared to a net loss of $41,055 during the three months ended December 31, 2022.

For the nine months ended December 31, 2023 and 2022

Revenue

During the nine months ended December 31, 2023 and 2022 the Company did not report any revenue from operations.

Operating Expenses

	Nine Months ended
	December 31,
	2023		2022

Expenses:
Selling, General and Administrative Expenses	$	52,496	$	54,706
Rent		13,932		13,152
Legal and Professional Expenses		58,595		45,673
Consulting Expense		30,000		10,000
Total Operating Expenses	$	155,023	$	123,531

During the nine months ended December 31, 2023 and 2022 the Company incurred operating expenses of $155,023 and $123,531 respectively. Selling, general and administrative expenses for the nine months ended December 31, 2023 were $52,496 a decrease of $2,210, compared to selling, general and administrative expenses of $54,706 during the nine months ended December 31, 2022. Selling, general and administrative expenses for the nine months ended December 31, 2023, consisted primarily of payroll and related costs of $36,000, and other selling, general, and administrative expenses of $16,496. Selling, general and administrative expenses for the nine months ended December 31, 2022 consisted primarily of payroll and related costs of $36,000 and administrative expenses of $18,706. The decrease was primarily due to a decrease in other general, and administrative expenses in the nine months ended December 31, 2023, when compared with the nine months ended December 31, 2022. Legal and professional fees increased from $45,673 in the nine months ended December 31, 2022 to $58,595 in the nine months ended December 31, 2023 predominantly as a result of fees associated with review engagements performed by our independent registered accounting firm with respect to our quarterly reporting requirements. Rent expense over the comparative nine months remained relatively consistent at $13,932 and $13,152, respectively for the nine months ended December 31, 2023 and 2022. Consulting expense for the nine months ended December 31, 2023 and 2022 totaled $30,000 and $10,000 respectively. Consulting expenses in the current nine months ended December 31, 2023 related to stock based compensation to a consultant by way of the issuance of 1,000,000 shares of common stock valued at $30,000.

Other Income/(Expense)

During the nine months ended December 31, 2023 the Company recorded other income of $74,678 as compared to other income of $4,620 in the nine months ended December 31, 2022.

Amortization of Debt Discount

Amortization of debt discounts for the comparative nine-month periods ended December 31, 2023, and 2022 totaled $0 and $69,451, respectively. The Company fully amortized remaining debt discounts during the fiscal year ended March 31, 2023.

Gain on Settlement of Debt

Gain on settlement of debt for the comparative nine-month periods ended December 31, 2023 and 2022 were $82,178, including forgiveness of previously accrued interest of $22,178 up to settlement date, and $25,000, respectively. The gain on settlement of debt for each of the nine-month periods ended December 31, 2023 and 2022 was due to settlements of convertible debts at less than face value.

Change in Derivative Liability

The Company recorded a gain of $60,567 with respect to the change in derivative liabilities for the nine months ended December 31, 2022, with no comparative results in the nine months ended December 31, 2023.

Interest Expense

Interest expense for the comparative nine months ended December 31, 2023 and 2022 totaled $7,500 and $11,496, respectively. The decrease to interest expense was directly related to a reduction to the principal balances of certain convertible debt period over period.

Net Loss

For the reasons stated above, our net loss for the nine months ended December 31, 2023 totaled $80,345, compared to a net loss of $118,911 during the nine months ended December 31, 2022.

Statement of Cash Flows

Nine months ended December 31, 2023 and 2022

The following table summarizes our cash flows for the comparative nine-month periods presented:

	December 31, 2023			December 31, 2022
Net cash used in operating activities	$	(56,758	)	$	(75,280	)
Net cash used in investing activities		—			—
Net cash provided by financing activities		54,342			54,727
Decrease in cash		(2,416	)		(20,553	)
Cash end of period	$	2,150		$	27,980

Operating activities

Net cash used by operating activities for the nine months ended December 31, 2023 was $56,758 compared to $75,280 used in the nine months ended December 31, 2022.

Investing activities

There was not cash used by or provided by investing activities in the nine months ended December 31, 2023 and 2022.

Financing activities

Our financing activities for the nine months ended December 31, 2023, provided cash of $54,342 as compared to cash from financing activities of $54,727 for the nine months ended December 31, 2022. We received $76,393 from a related party, offset by repayments to related parties of $2,051 in the nine months ended December 31, 2023, sold shares of common stock for proceeds of $20,000 and made repayments to settle certain convertible debt of $40,000. In the comparative nine months ended December 31, 2022 we received cash from related party of $158,000, offset by repayments to related party of $11,236, and made payments to reduce convertible debt of $64,650 and payments to reduce contingent liabilities of $70,350. We plan to raise additional capital during the current fiscal year.

Liquidity and Capital Resources

We are in need of additional cash resources to maintain our operations. As of December 31, 2023 and March 31, 2023, the Company had a working capital deficit of $649,484 and $455,285, respectively, and has incurred losses since inception of $34,660,846. These factors raise substantial doubt about its ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital or obtain necessary debt financing. The Company is presently dependent on its controlling shareholder to provide us funding for its daily operation and expenses, including professional fees and fees charged by regulators, although he is under no obligation to do so. Our auditors express substantial doubt about our ability to continue as a going concern. The Company intends to meet the cash requirements for the next 12 months from the issuance date of this report through a combination of debt and equity financing by way of private placements, friends, family and business associates. The Company currently does not have any arrangements in place to complete any private placement financings and there is no assurance that the Company will be successful in completing any such financings on terms that will be acceptable to it.

If we do not have sufficient working capital to pay our operating costs for the next 12 months, we will require additional funds to pay our legal, accounting and other fees associated with our Company and our filing obligations under United States federal securities laws, as well as to pay our other accounts payable generated in the ordinary course of our business. Once these costs are accounted for, we will focus on assembling a portfolio of early-stage EV Battery Technologies developed by Universities in Norway, Sweden and Finland

Any failure to raise money will have the effect of delaying the timeframes in the business plan as set forth above, and the Company may have to push back the dates of such activities.

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and further losses are anticipated as a result of the development of business which raises substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the issuance date of this report. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining financing necessary to meet the Company’s obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of the Company’s common stock.

Our cash and cash equivalents were $2,150 on December 31, 2023, compared to $4,566 on March 31, 2023. We met our liquidity needs through the issuance of our common stock and notes payable for cash.

We need to raise additional capital during the fiscal year, but currently have not acquired sufficient additional funding. Our ability to continue operations as a going concern is highly dependent upon our ability to obtain immediate additional financing, which can’t be guaranteed. Unless additional funding is obtained, it is highly unlikely that we can continue to operate. There is no assurance that even with adequate financing or combined operations, we will generate revenues and be profitable.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. The Company had a net loss of $80,345 and $118,911 for the nine months ended December 31, 2023, and December 31, 2022, respectively. The Company's accumulated deficit was $34,660,846 and $34,416,648 as of December 31, 2023, and March 31, 2023, respectively. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing. Our auditors express substantial doubt about our ability to continue as a going concern.

Off-Balance Sheet Arrangements

None.

Critical Accounting Estimates

We have adopted various accounting policies that govern the application of accounting principles generally accepted in the United States in the preparation of our financial statements. Our significant accounting policies are described in Note 3 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Certain accounting policies involve significant judgments and assumptions by our management that can have a material impact on the carrying value of certain assets and liabilities. We consider such accounting policies to be our critical accounting policies. The judgments and assumptions used by our management in these critical accounting policies are based on historical experience and other factors that our management believes to be reasonable under the circumstances. Because of the nature of these judgments and assumptions, actual results could differ significantly from these judgments and estimates, which could have a material impact on the carrying values of our assets and liabilities and our results of operations. Our critical accounting policies are described below.

Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to provide this information.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.

As of December 31, 2023, we carried out an evaluation, with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were not effective, as of December 31, 2023.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of December 31, 2023, of our internal control over financial reporting based on the framework in 2013 Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to material weaknesses in our internal control over financial reporting described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has concluded that material weaknesses existed as of December 31, 2023, as described below:

•

lack of segregation of duties due to a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements; and (ii) a lack of sufficient documented financial closing policies and procedures.

The material weaknesses did not result in any restatements of condensed consolidated financial statements previously reported by us, there were no changes in previously released financial results and management concluded that the consolidated financial statements included in this report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented, in conformity with accounting principles generally accepted in the United States.

Management has, and will continue to, allocate resources as available to its remediation plan, which include (i) the establishment of additional internal procedures with respect to the documentation of budget and forecasting process with respect to material assumptions or determinations, (ii) the implementation of additional processes to bolster accuracy of underlying assumptions and (iii) the implementation of more detailed month end and quarter close procedures for installation at our operating subsidiary location to enhance procedures currently in place. Management is committed to maintaining a strong internal control environment and allocating the necessary resources to remediate the identified material weaknesses.

Changes in Internal Control over Financial Reporting

There was no change in our system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A – RISK FACTORS

Please refer to the disclosure contained in “Risk Factors” in our Form 10 as filed with the SEC on September 14, 2023, as amended November 6, 2023. The risks described in the Form 10 are not the only risks that the Company faces. Additional risks and uncertainties not currently known to the Company, or that the Company currently deems to be immaterial, also may have a material adverse impact on the Company’s business, financial condition, or results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended December 31, 2023, the Company sold 1,000,000 shares of common stock at $0.02 per share for cash proceeds of $20,000.

The securities sale referenced above was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act as not involving a public offering and Regulation D, thereunder. The sale was made without any form of general solicitation to sophisticated investors and with full access to any information requested by the investor regarding us and the securities purchased.

There were no other sales of equity securities during the period covered by this Report that were not registered under the Securities Act and/or were not previously reported in a Current Report on Form 8-K filed by the Company.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

N/A

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number		Exhibit Description

3.1(a)		Articles of Incorporation*

3.1(b)		Articles of Merger*

3.1(c)		Agreement and Plan of Merger*

3.1(d)		Amended Articles of Incorporation*

3.1(e)		Amended and Restated Certificate of Incorporation of the Registrant*

3.2		Bylaws of the Registrant*

4.1(a)		Certificate of Designation of Series and Determination of Rights and Preferences of Series A Convertible Preferred Stock*

4.1(b)		Certificate of Designation*

4.1(c)		Amendment to Certificate of Designation After Issuance of Class or Series dated 3/14/2014*

4.1(d)		Amendment to Certificate of Designation After Issuance of Class or Series dated 01/12/2018*

10.1		Convertible Promissory Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 5, 2021*

10.2		Convertible Redeemable Note Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated March 7, 2022 *

10.3		Letter Agreement Between Groove Botanicals, Inc. and Robert L. Hymers, III Dated July 18, 2022 *

31.1		Certification of the Chief Executive and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

101		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Other Comprehensive Income, (iii) Condensed Consolidated Statements of Stockholders’ Equity (Deficit), (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
101.INS		INLINE XBRL INSTANCE DOCUMENT (THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT)
101.SCH		INLINE XBRL TAXONOMY EXTENSION SCHEMA
101.CAL		INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF		INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB		INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE		INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
104		COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)

________________

* Incorporated by reference to a previously filed exhibit or report.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Groove Botanicals, Inc.

Date: February 14, 2024	By:	/s/ Kent Rodriguez
		Kent Rodriguez
		Chief Executive Officer
		Chief Financial and Accounting Officer

EXHIBIT 31.1

CERTIFICATION

I, Kent Rodriguez, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Groove Botanicals Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 14, 2024

/s/ Kent Rodriguez

Kent Rodriguez

Chief Executive Officer, President, Secretary/Treasurer and Director (Principal Executive Officer and Principal Accounting and Financial Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Kent Rodriguez, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Quarterly Report on Form 10-Q of Groove Botanicals Inc. for the quarter ended December 31, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Groove Botanicals Inc.

Dated: February 14, 2024		/s/ Kent Rodriguez
		Kent Rodriguez
		Chief Executive Officer, President, Secretary/Treasurer and Director (Principal Executive Officer and Principal Accounting and Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Groove Botanicals Inc. and will be retained by Groove Botanicals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Cover - shares	9 Months Ended
Cover - shares	Dec. 31, 2023	Feb. 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	000-23476
Entity Registrant Name	GROOVE BOTANICALS, INC.
Entity Central Index Key	0000918573
Entity Tax Identification Number	84-1168832
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	310 Fourth Avenue South
Entity Address, Address Line Two	Suite 7000
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55415
City Area Code	(612)
Local Phone Number	315-5068
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,643,062

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current Assets:
Cash and Cash Equivalents	$ 2,150	$ 4,566
Accounts Receivable	25	25
Prepaid Expenses	330	390
Total Current Assets	2,505	4,982
TOTAL ASSETS	2,505	4,982
Current Liabilities:
Accounts Payable and Accrued Liabilities	76,694	44,489
Interest Payable		14,678
Related Party Payable	411,442	301,100
Convertible Notes Payable		100,000
Dividends Payable - Related Party	163,853
Total Current Liabilities	651,989	460,267
Total Liabilities	651,989	460,267
Stockholders' Deficit
Common Stock, $0.001 par value, 200,000,000 shares authorized; 59,643,062 and 57,643,062 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively	59,643	57,643
Additional paid-in capital	33,951,511	33,903,511
Accumulated deficit	(34,660,846)	(34,416,648)
Total stockholder's deficit	(649,484)	(455,285)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT	2,505	4,982
Series A Preferred Stock [Member]
Stockholders' Deficit
Preferred stock, value	10	10
Series B Preferred Stock [Member]
Stockholders' Deficit
Preferred stock, value	$ 198	$ 198

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2023	Mar. 31, 2023	Apr. 10, 2013	Sep. 28, 2012
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common stock, shares issued	59,643,062	57,643,062
Common stock, shares outstanding	59,643,062	57,643,062
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	1,983	1,983
Preferred stock, shares outstanding	1,983	1,983

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Expenses:
Selling, General and Administrative Expenses	$ 16,303	$ 15,467	$ 52,496	$ 54,706
Rent	4,644	4,644	13,932	13,152
Legal and Professional Expenses	34,525	7,504	58,595	45,673
Consulting Expense		10,000	30,000	10,000
Total Operating Expenses	55,472	37,615	155,023	123,531
Operating Loss	(55,472)	(37,615)	(155,023)	(123,531)
Other Income (Expense)
Amortization of Debt Discount		(7,561)		(69,451)
Change in Derivative Liability		7,811		60,567
Gain on Settlement of Debt	82,178		82,178	25,000
Interest Expense	(2,500)	(3,690)	(7,500)	(11,496)
Total Other Income (Expense)	79,678	(3,440)	74,678	4,620
Net income (loss)	24,206	(41,055)	(80,345)	(118,911)
Dividend on Preferred Stock	54,618		163,853
Loss attributed to common stockholders	$ (30,412)	$ (41,055)	$ (244,198)	$ (118,911)
Basic Earnings (Loss) per Common Share	$ 0.00	$ (0.00)	$ (0.00)	$ (0.00)
Diluted Earnings (Loss) per Common Share	$ 0.00	$ (0.00)	$ (0.00)	$ (0.00)
Weighted Average Number of Shares Outstanding, Basic	58,762,627	53,309,366	60,974,239	52,479,244
Weighted Average Number of Shares Outstanding, Diluted	58,762,627	53,309,366	60,974,239	52,479,244

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock Series A Stock [Member]	Preferred Stock Series B Stock [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2022	$ 10	$ 198	$ 49,193	$ 3,000	$ 33,798,656	$ (34,305,992)	$ (454,935)
Beginning balance, shares at Mar. 31, 2022	100	1,983	49,193,062	3,000,000
Issuance of Stock for Cash Received in Prior Period			$ 3,000	$ (3,000)
Issuance of Stock for Cash Received in Prior Period, shares			3,000,000	(3,000,000)
Net Income						23,745	23,745
Ending balance, value at Jun. 30, 2022	$ 10	$ 198	$ 52,193		33,798,656	(34,282,247)	(431,190)
Ending balance, shares at Jun. 30, 2022	100	1,983	52,193,062
Net Income						(101,601)	(101,601)
Ending balance, value at Sep. 30, 2022	$ 10	$ 198	$ 52,193		33,798,656	(34,383,848)	(532,791)
Ending balance, shares at Sep. 30, 2022	100	1,983	52,193,062
Issuance of Stock for Cash			$ 2,150		40,813		42,963
Issuance of Stock for Cash, shares			2,150,000
Issuance of Stock for Consulting			$ 500		9,500		42,963
Issuance of Stock for Consulting, shares			500,000
Net Income						(41,055)	(41,055)
Ending balance, value at Dec. 31, 2022	$ 10	$ 198	$ 54,843		33,848,969	(34,424,903)	(520,883)
Ending balance, shares at Dec. 31, 2022	100	1,983	54,843,062
Beginning balance, value at Mar. 31, 2023	$ 10	$ 198	$ 57,643		33,903,511	(34,416,648)	(455,285)
Beginning balance, shares at Mar. 31, 2023	100	1,983	57,643,062
Issuance of Stock for Consulting			$ 1,000		29,000		30,000
Issuance of Stock for Consulting, shares			1,000,000
Accrual of Preferred Dividends to Related Party						(54,618)	(54,618)
Net Income						(77,144)	(77,144)
Ending balance, value at Jun. 30, 2023	$ 10	$ 198	$ 58,643		33,932,511	(34,548,410)	(557,048)
Ending balance, shares at Jun. 30, 2023	100	1,983	58,643,062
Accrual of Preferred Dividends to Related Party						(54,618)	(54,618)
Net Income						(27,406)	(27,406)
Ending balance, value at Sep. 30, 2023	10	$ 198	$ 58,643		33,932,511	(34,630,434)	(639,072)
Ending balance, shares at Sep. 30, 2023		1,983	58,643,062
Issuance of Stock for Cash			$ 1,000		19,000		20,000
Issuance of Stock for Cash, shares			1,000,000
Accrual of Preferred Dividends to Related Party						(54,618)	(54,618)
Net Income						24,206	24,206
Ending balance, value at Dec. 31, 2023	$ 10	$ 198	$ 59,643		$ 33,951,511	$ (34,660,846)	$ (649,484)
Ending balance, shares at Dec. 31, 2023	100	1,983	59,643,062

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flow From Operating Activities
Net (Loss)	$ (80,345)	$ (118,911)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of Debt Discount		69,451
Change in Derivative Liability		(60,567)
Gain on Settlement of Debt	(82,178)	(25,000)
Stock-Based Compensation for Consulting	30,000	10,000
Accrued Interest	7,500	11,496
Accrued Payroll	36,000	36,000
Accounts Payable and Accrued Liabilities - Related Party		3,044
Changes in working capital
Decrease in Accounts Receivable		226
Decrease in Prepaid Expenses	60
Increase (Decrease) in Accounts Payable and Accrued Liabilities	32,205	(1,019)
Net Cash Used in Operating Activities	(56,758)	(75,280)
Cash Flow From Investing Activities
Net Cash Provided by (Used in) Investing Activities
Cash Flow From Financing Activities
Funds Received from Related Party	76,393	158,000
Funds Distributed to Related Party	(2,051)	(11,236)
Funds received from issuance of common stock	20,000	42,963
Repayment of Outstanding Convertible Debt	(40,000)	(64,650)
Repayment of Outstanding Contingent Liability		(70,350)
Net Cash Provided by (Used in) Financing Activities	54,342	54,727
Net Change in Cash	(2,416)	(20,553)
Cash at Beginning of Period	4,566	48,534
Cash at End of Period	2,150	27,980
Net cash paid for:
Interest
Income Taxes

ORGANIZATION AND OPERATIONS

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

ORGANIZATION AND OPERATIONS

NOTE 1 - ORGANIZATION AND OPERATIONS

Current Operations

Groove Botanicals (“GRVE” or the “Company” or the “Corporation”), a Nevada corporation, is a publicly quoted independent oil and gas producer.

Corporate History

In May 1999, we changed our state of domicile to Nevada and our name to XDOGS.COM, Inc.

On July 31, 1998, the Corporation split their shares One (1) for Fifty-Four (54).

On August 24, 2000, the Corporation split their shares One (1) for Five (5) and changed our name from XDOGS.COM to XDOGS, Inc. We changed our symbol from XDGS to XDGI.

On June 22, 2005, the Corporation changed our name from XDOGS, Inc. to Avalon Oil and Gas, Inc. We changed our symbol from XDGI to AOGS.

On May 15, 2007, the Corporation split their shares One (1) for Twenty (20). We changed our symbol from AOGS to AOGN.

On July 23, 2012, the Corporation split their shares One (1) for Three Hundred (300).

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Financial Instruments

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Net Loss Per Share

Recently Adopted Accounting Pronouncements

Income Taxes

Beneficial Conversion Feature

Debt Issuance Cost

GOING CONCERN

9 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3 - GOING CONCERN

CASH

9 Months Ended

Dec. 31, 2023

Cash and Cash Equivalents [Abstract]

CASH

NOTE 4 – CASH

FAIR VALUE OF FINANCIAL INSTRUMENTS

9 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE OF FINANCIAL INSTRUMENTS

NOTE 5 – FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3		Pricing inputs that are generally observable inputs and not corroborated by market data.

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

9 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

RELATED PARTY TRANSACTIONS

9 Months Ended

Dec. 31, 2023

RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

During the nine months ended December 31, 2023, the Company received accumulated advances for operational shortfalls of $76,393 from a related party.

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Dec. 31, 2023

Disclosure Convertible Notes Payable Abstract

CONVERTIBLE NOTES PAYABLE

NOTE 8 – CONVERTIBLE NOTES PAYABLE

(a)

(b)

(c)

(d)

(e)

The Company had convertible notes payable of $0 and $100,000 outstanding as of December 31, 2023, and March 31, 2023.

Schedule of convertible note payable
	December 31, 2023		March 31, 2023
Beginning Balance	$	100,000	$	164,774
Repayments in cash		(40,000)		(139,650	)
Extinguishment under settlement agreement		(60,000)		(139,650	)
Amortization of discounts		—		74,876
Convertible notes payable, net (Ending Balance)	$	—	$	100,000

Below is the summary of the principal balance and debt discounts as of December 31, 2023:


Convertible Promissory Note Holder	Start Date	End Date	Initial Note Principal Balance	Debt Discounts as of Issuance	Amortization	Debt Discounts as of December 31, 2023 and March 31, 2023
Robert Hymers III	3/5/2021	6/30/2022	$40,000	$40,000	($40,000)		—
Robert Hymers III	3/7/2022	3/7/2023	$60,000	$30,000	($30,000)		—
Total							—
Remaining note principal balance						$	—
Total convertible promissory notes, net						$	—

PREFERRED STOCK

9 Months Ended

Dec. 31, 2023

Equity [Abstract]

PREFERRED STOCK

NOTE 9 – PREFERRED STOCK

COMMON STOCK

9 Months Ended

Dec. 31, 2023

Equity [Abstract]

COMMON STOCK

NOTE 10 – COMMON STOCK

The Company is authorized to issue 200,000,000 shares of Common Stock, with a par value of $0.001.

On April 8, 2022, the Company issued 2,500,000 shares of common stock, of which it had previously committed in exchange for $40,000 it had received on March 23, 2022.

On April 15, 2023, the Company issued 1,000,000 shares of common stock in exchange for consulting services. These shares were valued at $0.03 per shares per their corresponding consulting agreement.

On December 20, 2023, the Company issued 1,000,000 shares of common stock in exchange for $20,000 in cash proceeds.

The Company had 59,643,062 and 57,643,062 shares of common stock issued and outstanding as of December 31, 2023, and March 31, 2023, respectively.

DERIVATIVE FINANCIAL INSTRUMENTS

9 Months Ended

Dec. 31, 2023

Investments, All Other Investments [Abstract]

DERIVATIVE FINANCIAL INSTRUMENTS

NOTE 11 – DERIVATIVE FINANCIAL INSTRUMENTS

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 12: COMMITMENTS AND CONTINGENCIES

As of December 31, 2023, the Company has a month-to-month verbal lease agreement with the landlord, in which the Company is obligated to pay $1,200 on a monthly basis.

SUBSEQUENT EVENTS

9 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 13 – SUBSEQUENT EVENTS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Financial Instruments

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Net Loss Per Share

Recently Adopted Accounting Pronouncements

Income Taxes

Beneficial Conversion Feature

Debt Issuance Cost

CONVERTIBLE NOTES PAYABLE (Tables)

9 Months Ended

Dec. 31, 2023

Disclosure Convertible Notes Payable Abstract

Schedule of convertible note payable

Schedule of convertible note payable
	December 31, 2023		March 31, 2023
Beginning Balance	$	100,000	$	164,774
Repayments in cash		(40,000)		(139,650	)
Extinguishment under settlement agreement		(60,000)		(139,650	)
Amortization of discounts		—		74,876
Convertible notes payable, net (Ending Balance)	$	—	$	100,000

Schedule of convertible promissory notes


Convertible Promissory Note Holder	Start Date	End Date	Initial Note Principal Balance	Debt Discounts as of Issuance	Amortization	Debt Discounts as of December 31, 2023 and March 31, 2023
Robert Hymers III	3/5/2021	6/30/2022	$40,000	$40,000	($40,000)		—
Robert Hymers III	3/7/2022	3/7/2023	$60,000	$30,000	($30,000)		—
Total							—
Remaining note principal balance						$	—
Total convertible promissory notes, net						$	—

ORGANIZATION AND OPERATIONS (Details Narrative) - $ / shares	1 Months Ended
	Jul. 23, 2012	Dec. 31, 2023	Mar. 31, 2023	Apr. 10, 2013	Sep. 28, 2012	Jul. 22, 2005
Common stock shares authorized		200,000,000	200,000,000	200,000,000	200,000,000
Common stock par value		$ 0.001	$ 0.001
Stock split description	the Corporation split their shares One (1) for Three Hundred (300).
Avalon Oil And Gas Inc. [Member]
Common stock shares authorized						1,000,000,000
Common stock par value						$ 0.001

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (24,206)	$ 41,055	$ 80,345	$ 118,911
Accumulated deficit	$ 34,660,846		$ 34,660,846		$ 34,416,648

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	$ 49,694	$ 44,489

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		9 Months Ended
	Apr. 02, 2020	Dec. 31, 2023	Mar. 31, 2023	Jun. 03, 2022
Related Party Transaction [Line Items]
Related party payment outstanding		$ 411,442	$ 301,100
Wages payable		48,000
Related party debt		76,393		$ 125,000
Chief Executive Officer [Member] \| Kent Rodriguez [Member]
Related Party Transaction [Line Items]
Monthly wages payment		$ 4,000
Description of employment agreement	the Company entered into an employment agreement with its CEO which designates monthly payments due to CEO Kent Rodriguez in the amount of $4,000 each month. This agreement shall continue for four years until March 31, 2024. These payables accrue no interest and have no maturity date.

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	9 Months Ended	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Disclosure Convertible Notes Payable Abstract
Beginning Balance	$ 100,000	$ 164,774
Repayments in cash	(40,000)	(139,650)
Extinguishment under settlement agreement	(60,000)	(139,650)
Amortization of discounts		74,876
Convertible notes payable, net (Ending Balance)		$ 100,000

CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	9 Months Ended
CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Discounts
Remaining note principal balance
Total convertible promissory notes, net
Robert Hymers III [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Start Date	Mar. 05, 2021
End Date	Jun. 30, 2022
Initial Note Principal Balance	$ 40,000
Debt Discounts as of Issuance	40,000
Amortization	(40,000)
Debt Discounts
Robert Hymers III One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Start Date	Mar. 07, 2022
End Date	Mar. 07, 2023
Initial Note Principal Balance	$ 60,000
Debt Discounts as of Issuance	30,000
Amortization	(30,000)
Debt Discounts

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)				1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 03, 2022	Oct. 01, 2021	Jun. 03, 2021	Dec. 31, 2023	Mar. 29, 2023	Dec. 31, 2022	Feb. 22, 2022	Jul. 23, 2021	Jan. 30, 2018	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2023	Mar. 28, 2023	Jan. 23, 2023	Mar. 07, 2022	Mar. 05, 2021	Mar. 31, 2019
Short-Term Debt [Line Items]
Accrued interest payable																$ 14,678
Amortization of debt discount											$ 7,561		$ 69,451
Convertible notes payable														$ 164,774		100,000
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Debt interest rate									10.00%
Maturity date									Jan. 30, 2019
Debt instrument principal amount									$ 230,000
Accrued interest payable																					$ 27,957
Convertible Promissory Note [Member] \| Settlement Agreement [Member]
Short-Term Debt [Line Items]
Convertible note	$ 54,650		$ 54,650
Contingent liability	95,350		$ 95,350
Settlement agreement description			This recognition came as part of a settlement agreement reached on June 3, 2021, in which the prior $230,000 convertible note, as well as approximately $72,458 of related interest was settled into a new convertible debt of $54,650, a contingent liability of $95,350, and two cash payments of $50,000 each to the note holder, which were made on July 20, 2020, and March 10, 2021.
Gain on debt extinguishment			$ 52,000
Settlement payment	125,000
Gain on settlement of debt	25,000
Cash payment	$ 50,000
Convertible Promissory Note [Member] \| Third Party [Member]
Short-Term Debt [Line Items]
Convertible promissory note									$ 230,000
Convertible Promissory Note 2 [Member]
Short-Term Debt [Line Items]
Debt interest rate																				10.00%
Debt instrument principal amount																		$ 60,000		$ 40,000
Accrued interest payable																		40,000
Convertible note				0						0		0				40,000
Debt instrument conversion price																				$ 0.02
Amortization of debt discount														37,151	$ 2,849
Convertible notes payable				0						0		0				100,000
Convertible Promissory Note 2 [Member] \| Settlement Agreement [Member]
Short-Term Debt [Line Items]
Settlement payment				40,000
Gain on settlement of debt				82,178
Settlement interest				22,178
Convertible Promissory Note 2 [Member] \| Third Party [Member]
Short-Term Debt [Line Items]
Convertible promissory note																				$ 40,000
Convertible Promissory Note 3 [Member]
Short-Term Debt [Line Items]
Convertible promissory note								$ 45,000									$ 45,000
Debt interest rate								8.00%
Maturity date								Mar. 31, 2023
Accrued interest payable																	5,000
Convertible note						$ 25,000					$ 25,000		$ 25,000	$ 35,000
Repayments of debt						20,000
Remaining balance																	$ 30,000
Wired fee					$ 5,000
Convertible Promissory Note 4 [Member]
Short-Term Debt [Line Items]
Convertible promissory note		$ 50,000
Debt interest rate		5.00%
Debt instrument principal amount		$ 50,000
Debt instrument conversion price		$ 0.02
Amortization of debt discount						$ 50,000
Proceeds from convertible debt		$ 50,000
Debt instrument conversion shares							2,750,000
Convertible Promissory Note 5 [Member]
Short-Term Debt [Line Items]
Convertible promissory note																			$ 60,000
Debt interest rate																			10.00%
Debt instrument principal amount																		40,000
Accrued interest payable																		$ 40,000
Convertible note				0						$ 0		$ 0				$ 60,000
Debt instrument conversion price																			$ 0.02
Convertible Promissory Note 5 [Member] \| Settlement Agreement [Member]
Short-Term Debt [Line Items]
Settlement payment				40,000
Gain on settlement of debt				82,178
Settlement interest				$ 22,178

PREFERRED STOCK (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
PREFERRED STOCK (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Class of Stock [Line Items]
Liquidation preference, value	$ 500,000		$ 500,000
Liquidation preference per share	$ 5,000		$ 5,000
Accrued preferred dividends	$ 54,618		$ 163,853
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	100		100		100
Preferred stock, par value	$ 0.10		$ 0.10		$ 0.10
Preferred stock, shares issued	100		100		100
Preferred stock, shares outstanding	100		100		100
Accrued preferred dividends	$ 10,000		$ 30,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	2,000		2,000		2,000
Preferred stock, par value	$ 0.10		$ 0.10		$ 0.10
Preferred stock, shares issued	1,983		1,983		1,983
Preferred stock, shares outstanding	1,983		1,983		1,983
Accrued preferred dividends	$ 44,617		$ 133,853

COMMON STOCK (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
COMMON STOCK (Details Narrative) - USD ($)	Apr. 08, 2022	Dec. 20, 2023	Apr. 15, 2022	Jun. 30, 2022	Dec. 31, 2023	Mar. 31, 2023	Apr. 10, 2013	Sep. 28, 2012
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares authorized					200,000,000	200,000,000	200,000,000	200,000,000
Common stock, par value					$ 0.001	$ 0.001
Stock issued during the period, shares	2,500,000	1,000,000
Stock issued during the period, value	$ 40,000
Proceeds from common stock		$ 20,000
Common stock, shares issued					59,643,062	57,643,062
Common stock, shares outstanding					59,643,062	57,643,062
Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued in exchange for consulting services			1,000,000
Share Price			$ 0.03
Two Separate Parties [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during the period, shares	500,000
Stock issued during the period, value	$ 10,000

DERIVATIVE FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Derivative liabilities	$ 0	$ 0

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			9 Months Ended
	Jun. 03, 2022	Jun. 03, 2021	Dec. 31, 2023	Jan. 30, 2018
Short-Term Debt [Line Items]
Verbal lease agreement description			Company has a month-to-month verbal lease agreement with the landlord, in which the Company is obligated to pay $1,200 on a monthly basis.
Convertible Promissory Note [Member] \| Settlement Agreement [Member]
Short-Term Debt [Line Items]
Convertible debt	$ 54,650	$ 54,650
Contingent liability	95,350	$ 95,350
Settlement agreement description		This recognition came as part of a settlement agreement reached on June 3, 2021, in which the prior $230,000 convertible note, as well as approximately $72,458 of related interest was settled into a new convertible debt of $54,650, a contingent liability of $95,350, and two cash payments of $50,000 each to the note holder, which were made on July 20, 2020, and March 10, 2021.
Gain on debt extinguishment		$ 52,000
Loan from a related party	125,000
Settlement payment	125,000
Gain on settlement of debt	$ 25,000
Convertible Promissory Note [Member] \| Third Party [Member]
Short-Term Debt [Line Items]
Convertible promissory note				$ 230,000

Groove Botanicals (PK) (USOTC:GRVE)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Groove Botanicals (PK) Charts.

Groove Botanicals (PK) (USOTC:GRVE)
Historical Stock Chart
From Nov 2023 to Nov 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

GRVE Groove Botanicals Inc (PK)

Groove Botanicals Inc (PK) News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

GRVE Groove Botanicals Inc (PK)

Groove Botanicals Inc (PK) News

Your Recent History

Company

Business

Popular

Get The App